FGP
PCVX icon

Freestone Grove Partners’s Vaxcyte PCVX Stock Holding History

Freestone Grove Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-224,731
Closed -$13.1M – 1250
2026
Q1 		$13.1M Buy
+224,731
New +$12.2M 0.09% 262
2025
Q3 		– Sell
-6,461
Closed -$210K – 861
2025
Q2 		$210K Buy
+6,461
New +$212K ﹤0.01% 628

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Freestone Grove Partners's PCVX Position: Q2 2026 in Review

Freestone Grove Partners sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 224,731 shares — an estimated $13.1M sold.

Freestone Grove Partners first reported a position in PCVX in Q2 2025 and held it in 2 quarters. The position peaked at $13.1M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Freestone Grove Partners reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 224,731 Vaxcyte shares in Q2 2026, an estimated $13.1M.
  • Freestone Grove Partners first reported a position in Vaxcyte in Q2 2025 and held it in 2 quarters.
  • Freestone Grove Partners's Vaxcyte position peaked at $13.1M in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.